<abstract xmlns="http://www.w3.org/1999/xhtml"> Backgrounds: Uterine sarcoma was staged previously according to the 1988 FIGO staging system for endometrial adenocarcinoma. However, in 2009 a new staging system for uterine sarcoma has been developed. Objectives: The purpose of this study was to compare the survival between traditional and new FIGO staging system. Materials and methods: The medical records of uterine sarcoma patients who received primary treatment at King Chulalongkorn Memorial Hospital, Thailand between 1999 and 2008 were reviewed. The survival curves were generated by Kaplan-Meier method. A comparison of survival between groups was assessed by the log-rank test. Results: Thirty-three patients were included. The incidence of uterine sarcoma was 0.8% and 4.4% of all gynecologic cancers and uterine cancer, respectively. A comparison between these two staging systems showed that four patients (12.1%) were down-staged and none was up-staged. The 5-year disease-free survival (DFS) and overall survival (OS) were 40.4% and 56.0%, respectively. Age, parity, histology, tumor size, lymph node dissection, and adjuvant treatments were not significant prognostic factors. Patients with early stage had significantly longer survival than those with advanced stage. Mean DFS in early stage according to 1988 and 2009 FIGO staging system were 80 and 77 months, respectively. Mean OS were 97 months and 91 months, respectively. Mean DFS in advanced stage were 34 months and 15 months, respectively. Median OS were 12 months and 10 months, respectively. There was no difference in survival between these two staging systems. Conclusions: Stage is the only independent prognostic factor. There was no difference in survival between these two staging systems.</abstract>

Backgrounds: Uterine sarcoma was staged previously according to the 1988 FIGO staging system for endometrial adenocarcinoma. However, in 2009 a new staging system for uterine sarcoma has been developed. Objectives: The purpose of this study was to compare the survival between traditional and new FIGO staging system. Materials and methods: The medical records of uterine sarcoma patients who received primary treatment at King Chulalongkorn Memorial Hospital, Thailand between 1999 and 2008 were reviewed. The survival curves were generated by Kaplan-Meier method. A comparison of survival between groups was assessed by the log-rank test. Results: Thirty-three patients were included. The incidence of uterine sarcoma was 0.8% and 4.4% of all gynecologic cancers and uterine cancer, respectively. A comparison between these two staging systems showed that four patients (12.1%) were down-staged and none was up-staged. The 5-year disease-free survival (DFS) and overall survival (OS) were 40.4% and 56.0%, respectively. Age, parity, histology, tumor size, lymph node dissection, and adjuvant treatments were not significant prognostic factors. Patients with early stage had significantly longer survival than those with advanced stage. Mean DFS in early stage according to 1988 and 2009 FIGO staging system were 80 and 77 months, respectively. Mean OS were 97 months and 91 months, respectively. Mean DFS in advanced stage were 34 months and 15 months, respectively. Median OS were 12 months and 10 months, respectively. There was no difference in survival between these two staging systems. Conclusions: Stage is the only independent prognostic factor. There was no difference in survival between these two staging systems.

The comparison of 1988 and 2009 FIGO staging system for uterine sarcoma in King Chulalongkorn Memorial Hospital during 1999-2008

Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330,

MD, Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Backgrounds: Uterine sarcoma was staged previously according to the 1988 FIGO staging system for endometrial adenocarcinoma. However, in 2009 a new staging...

The comparison of 1988 and 2009 FIGO staging system for uterine sarcoma in King Chulalongkorn Memorial Hospital during 1999-2008

Article Category: Original article

Data publikacji: 04 lut 2017

Zakres stron: 807 - 816

DOI: https://doi.org/10.5372/1905-7415.0506.105

Słowa kluczowe
FIGO staging system, prognosis, survival, uterine sarcoma

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The comparison of 1988 and 2009 FIGO staging system for uterine sarcoma in King Chulalongkorn Memorial Hospital during 1999-2008

Article Category: Original article

Data publikacji: 04 lut 2017

Zakres stron: 807 - 816

DOI: https://doi.org/10.5372/1905-7415.0506.105

Słowa kluczoweFIGO staging system, prognosis, survival, uterine sarcoma

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
FIGO staging system, prognosis, survival, uterine sarcoma